Campbell McInnes

Title
InstitutionMedical University of South Carolina
DepartmentSCCP Pharmaceutical and Biomedical Sciences - USC Campus
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Zhang L, Cheng C, Li J, Wang L, Chumanevich AA, Porter DC, Mindich A, Gorbunova S, Roninson IB, Chen M, McInnes C. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022 02 24; 65(4):3420-3433. PMID: 35114084.
      Citations:    
    2. Craig SN, Baxter M, Chapagai D, Stafford JM, Nurmemmedov E, Altomare D, Wyatt MD, McInnes C. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926. PMID: 34735919.
      Citations:    
    3. Chapagai D, Ramamoorthy G, Varghese J, Nurmemmedov E, McInnes C, Wyatt MD. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. J Med Chem. 2021 07 22; 64(14):9916-9925. PMID: 34210138.
      Citations:    
    4. Baxter M, Chapagai D, Craig S, Hurtado C, Varghese J, Nurmemmedov E, Wyatt MD, McInnes C. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. ChemMedChem. 2020 06 17; 15(12):1058-1066. PMID: 32232973.
      Citations:    
    5. Beneker CM, Rovoli M, Kontopidis G, Röring M, Galda S, Braun S, Brummer T, McInnes C. Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. J Med Chem. 2019 04 25; 62(8):3886-3897. PMID: 30977659.
      Citations:    
    6. Pearson RJ, Blake DG, Mezna M, Fischer PM, Westwood NJ, McInnes C. The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1. Cell Chem Biol. 2018 09 20; 25(9):1107-1116.e4. PMID: 30017915.
      Citations:    
    7. Gao J, Midde N, Zhu J, Terry AV, McInnes C, Chapman JM. Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2016 11 15; 26(22):5573-5579. PMID: 27769620.
      Citations:    
    8. Premnath PN, Craig SN, Liu S, McInnes C. Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy. Bioorg Med Chem Lett. 2016 08 01; 26(15):3754-60. PMID: 27297568.
      Citations:    
    9. Grigoroudis AI, McInnes C, Premnath PN, Kontopidis G. Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones. Protein Expr Purif. 2015 Sep; 113:8-16. PMID: 25956535.
      Citations:    
    10. Premnath PN, Craig SN, Liu S, Anderson EL, Grigoroudis AI, Kontopidis G, Perkins TL, Wyatt MD, Pittman DL, McInnes C. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. J Med Chem. 2015 Jan 08; 58(1):433-42. PMID: 25454794.
      Citations:    
    11. Papaneophytou CP, Grigoroudis AI, McInnes C, Kontopidis G. Quantification of the effects of ionic strength, viscosity, and hydrophobicity on protein-ligand binding affinity. ACS Med Chem Lett. 2014 Aug 14; 5(8):931-6. PMID: 25147617.
      Citations:    
    12. Craig SN, Wyatt MD, McInnes C. Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov. 2014 Jul; 9(7):773-89. PMID: 24819909.
      Citations:    
    13. Premnath PN, Liu S, Perkins T, Abbott J, Anderson E, McInnes C. Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors. Bioorg Med Chem. 2014 Jan 01; 22(1):616-22. PMID: 24286762.
      Citations:    
    14. Wang P, McInnes C, Zhu BT. Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor a and ß subtypes: a molecular modeling study. PLoS One. 2013; 8(9):e74615. PMID: 24098659.
      Citations:    
    15. Liu S, Premnath PN, Bolger JK, Perkins TL, Kirkland LO, Kontopidis G, McInnes C. Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly. J Med Chem. 2013 Feb 28; 56(4):1573-82. PMID: 23323521.
      Citations:    
    16. McInnes C, Estes K, Baxter M, Yang Z, Farag DB, Johnston P, Lazo JS, Wang J, Wyatt MD. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Mol Cancer Ther. 2012 Aug; 11(8):1683-92. PMID: 22848093.
      Citations:    
    17. Smith MA, McInnes C, Whitaker RM, Lindsey CC, Comer RF, Beeson CC, Schnellmann RG. Calpain 10 homology modeling with CYGAK and increased lipophilicity leads to greater potency and efficacy in cells. ACS Chem Biol. 2012 Aug 17; 7(8):1410-9. PMID: 22612451.
      Citations:    
    18. McInnes C, Wyatt MD. PLK1 as an oncology target: current status and future potential. Drug Discov Today. 2011 Jul; 16(13-14):619-25. PMID: 21601650.
      Citations:    
    19. Wang S, Griffiths G, Midgley CA, Barnett AL, Cooper M, Grabarek J, Ingram L, Jackson W, Kontopidis G, McClue SJ, McInnes C, McLachlan J, Meades C, Mezna M, Stuart I, Thomas MP, Zheleva DI, Lane DP, Jackson RC, Glover DM, Blake DG, Fischer PM. Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol. 2010 Oct 29; 17(10):1111-21. PMID: 21035734.
      Citations:    
    20. Liu S, Bolger JK, Kirkland LO, Premnath PN, McInnes C. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements. ACS Chem Biol. 2010 Dec 17; 5(12):1169-82. PMID: 20843055.
      Citations:    
    21. Wang S, Midgley CA, Scaërou F, Grabarek JB, Griffiths G, Jackson W, Kontopidis G, McClue SJ, McInnes C, Meades C, Mezna M, Plater A, Stuart I, Thomas MP, Wood G, Clarke RG, Blake DG, Zheleva DI, Lane DP, Jackson RC, Glover DM, Fischer PM. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010 Jun 10; 53(11):4367-78. PMID: 20462263.
      Citations:    
    22. McIntyre NA, McInnes C, Griffiths G, Barnett AL, Kontopidis G, Slawin AM, Jackson W, Thomas M, Zheleva DI, Wang S, Blake DG, Westwood NJ, Fischer PM. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors. J Med Chem. 2010 Mar 11; 53(5):2136-45. PMID: 20146435.
      Citations:    
    23. Kontopidis G, Andrews MJ, McInnes C, Plater A, Innes L, Renachowski S, Cowan A, Fischer PM. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design. ChemMedChem. 2009 Jul; 4(7):1120-8. PMID: 19472269.
      Citations:    
    24. Nadkarni A, Furda A, Rajesh C, McInnes C, Ruch RJ, Pittman DL. Functional characterization of the RAD51D E233G genetic variant. Pharmacogenet Genomics. 2009 Feb; 19(2):153-60. PMID: 19033885.
      Citations:    
    25. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86. PMID: 19072652.
      Citations:    
    26. McInnes C. Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug Discov Today. 2008 Oct; 13(19-20):875-81. PMID: 18639646.
      Citations:    
    27. McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol. 2007 Oct; 11(5):494-502. PMID: 17936059.
      Citations:    
    28. Andrews MJ, Kontopidis G, McInnes C, Plater A, Innes L, Cowan A, Jewsbury P, Fischer PM. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors. Chembiochem. 2006 Dec; 7(12):1909-15. PMID: 17051658.
      Citations:    
    29. McInnes C, Mazumdar A, Mezna M, Meades C, Midgley C, Scaerou F, Carpenter L, Mackenzie M, Taylor P, Walkinshaw M, Fischer PM, Glover D. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol. 2006 Nov; 2(11):608-17. PMID: 17028581.
      Citations:    
    30. McInnes C, Mezna M, Kontopidis G. Catch the kinase conformer. Chem Biol. 2006 Jul; 13(7):693-4. PMID: 16873016.
      Citations:    
    31. McInnes C. Improved lead-finding for kinase targets using high-throughput docking. Curr Opin Drug Discov Devel. 2006 May; 9(3):339-47. PMID: 16729730.
      Citations:    
    32. Thomas MP, McInnes C. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle. IDrugs. 2006 Apr; 9(4):273-8. PMID: 16596481.
      Citations:    
    33. Kontopidis G, McInnes C, Pandalaneni SR, McNae I, Gibson D, Mezna M, Thomas M, Wood G, Wang S, Walkinshaw MD, Fischer PM. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. Chem Biol. 2006 Feb; 13(2):201-11. PMID: 16492568.
      Citations:    
    34. Thomas MP, McInnes C, Fischer PM. Protein structures in virtual screening: a case study with CDK2. J Med Chem. 2006 Jan 12; 49(1):92-104. PMID: 16392795.
      Citations:    
    35. Uhrinova S, Uhrin D, Powers H, Watt K, Zheleva D, Fischer P, McInnes C, Barlow PN. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol. 2005 Jul 15; 350(3):587-98. PMID: 15953616.
      Citations:    
    36. McInnes C. PharmaDiscovery 2005. Kinases in drug discovery. IDrugs. 2005 Jul; 8(7):551-4. PMID: 15973561.
      Citations:    
    37. Kontopidis G, Wu SY, Zheleva DI, Taylor P, McInnes C, Lane DP, Fischer PM, Walkinshaw MD. Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A. 2005 Feb 08; 102(6):1871-6. PMID: 15681588.
      Citations:    
    38. McInnes C, Fischer PM. Strategies for the design of potent and selective kinase inhibitors. Curr Pharm Des. 2005; 11(14):1845-63. PMID: 15892678.
      Citations:    
    39. McInnes C, Mezna M, Fischer PM. Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem. 2005; 5(2):181-97. PMID: 15853646.
      Citations:    
    40. Andrews MJ, McInnes C, Kontopidis G, Innes L, Cowan A, Plater A, Fischer PM. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Org Biomol Chem. 2004 Oct 07; 2(19):2735-41. PMID: 15455144.
      Citations:    
    41. Wang S, Wood G, Meades C, Griffiths G, Midgley C, McNae I, McInnes C, Anderson S, Jackson W, Mezna M, Yuill R, Walkinshaw M, Fischer PM. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. Bioorg Med Chem Lett. 2004 Aug 16; 14(16):4237-40. PMID: 15261277.
      Citations:    
    42. McInnes C, Wang S, Anderson S, O'Boyle J, Jackson W, Kontopidis G, Meades C, Mezna M, Thomas M, Wood G, Lane DP, Fischer PM. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol. 2004 Apr; 11(4):525-34. PMID: 15123247.
      Citations:    
    43. Wang S, Meades C, Wood G, Osnowski A, Anderson S, Yuill R, Thomas M, Mezna M, Jackson W, Midgley C, Griffiths G, Fleming I, Green S, McNae I, Wu SY, McInnes C, Zheleva D, Walkinshaw MD, Fischer PM. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem. 2004 Mar 25; 47(7):1662-75. PMID: 15027857.
      Citations:    
    44. Kontopidis G, Andrews MJ, McInnes C, Cowan A, Powers H, Innes L, Plater A, Griffiths G, Paterson D, Zheleva DI, Lane DP, Green S, Walkinshaw MD, Fischer PM. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure. 2003 Dec; 11(12):1537-46. PMID: 14656438.
      Citations:    
    45. Wu SY, McNae I, Kontopidis G, McClue SJ, McInnes C, Stewart KJ, Wang S, Zheleva DI, Marriage H, Lane DP, Taylor P, Fischer PM, Walkinshaw MD. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure. 2003 Apr; 11(4):399-410. PMID: 12679018.
      Citations:    
    46. McInnes C, Andrews MJ, Zheleva DI, Lane DP, Fischer PM. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr Med Chem Anticancer Agents. 2003 Jan; 3(1):57-69. PMID: 12678915.
      Citations:    
    47. Mercer AA, Wise LM, Scagliarini A, McInnes CJ, Büttner M, Rziha HJ, McCaughan CA, Fleming SB, Ueda N, Nettleton PF. Vascular endothelial growth factors encoded by Orf virus show surprising sequence variation but have a conserved, functionally relevant structure. J Gen Virol. 2002 Nov; 83(Pt 11):2845-2855. PMID: 12388821.
      Citations:    
    48. Atkinson GE, Cowan A, McInnes C, Zheleva DI, Fischer PM, Chan WC. Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe. Bioorg Med Chem Lett. 2002 Sep 16; 12(18):2501-5. PMID: 12182847.
      Citations:    
    49. Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999 Jul; 134(7):764-7. PMID: 26554946.
      Citations:    
    50. Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999 Jul; 134(7):764-7. PMID: 19327148.
      Citations:    
    51. Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999 Jul; 134(7):764-7. PMID: 19167366.
      Citations:    
    McInnes's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (205)
    Explore
    _
    Co-Authors (8)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _